A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

Trial Profile

A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Lobeglitazone (Primary)
  • Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ELLEGANCE
  • Most Recent Events

    • 01 Jan 2017 Results published in the Journal of Korean Medical Science
    • 01 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 08 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top